Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Deep brain stimulation can also affect respiratory function

Deep brain stimulation (DBS) has become a common treatment for patients with chronic pain or movement disorders. Now a unique set of experiments shows that electrical stimulation in some of the same brain areas can also affect respiratory function, according to a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

16 Feb 2012

Soft drink consumption associated with increased chance of asthma, COPD

A new study published in the journal Respirology reveals that a high level of soft drink consumption is associated with asthma and/or chronic obstructive pulmonary disease (COPD).

8 Feb 2012

High soft drink consumption associated with asthma and COPD

A new study published in the journal Respirology reveals that a high level of soft drink consumption is associated with asthma and/or chronic obstructive pulmonary disease (COPD).

7 Feb 2012

Janssen, Orexo to end OX-CLI/OX-ESI research collaboration and license agreement

Orexo AB and Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV, have decided to end their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs and a third, undisclosed Janssen program.

31 Jan 2012

CAT can assess exacerbation severity in patients with COPD

Exacerbation severity in patients with chronic obstructive pulmonary disease (COPD) can be reliably assessed with the COPD Assessment Test- (CAT), according to a new study from the UK.

27 Jan 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012

Economic burden of job-related injuries and illnesses in the U.S.

In the first comprehensive review of its kind since 1992, a UC Davis researcher has estimated the national annual price tag of occupational injuries and illnesses at $250 billion, much higher than generally assumed.

19 Jan 2012

Health influence of combustion conditions in wood-burning stoves

Wood-burning stoves are a popular source of heating in many countries. However in recent years there has been much debate about the potential negative health effects associated with wood smoke. A Norwegian researcher has studied the influence of combustion conditions on the emissions and their health effects.

18 Jan 2012

Vitamin D provides no relief from chronic obstructive pulmonary disease

Earlier studies have suggested that up to three quarters of people with severe chronic obstructive pulmonary disease, or COPD, are deficient in the vitamin. So it was thought that giving them extra vitamin D might help prevent exacerbations in symptoms or trips to the hospital because of shortness of breath or mucus in the airways. Belgian researchers have refuted this claim.

17 Jan 2012

SAA protein plays a key role in chronic inflammation and lung damage in COPD

Sufferers of smoking related lung diseases could have their debilitating symptoms reduced following the discovery of a potential new treatment.

13 Jan 2012

Tobacco more harmful to lungs than marijuana

A large-scale national study suggests low to moderate use of marijuana is less harmful to users' lungs than exposure to tobacco, even though the two substances contain many of the same components. This comprehensive study, led by UCSF and University of Alabama at Birmingham, collected data from more than 5,000 U.S. adults for more than 20 years.

11 Jan 2012

Celtaxsys announces acquisition of CTX-4430 from Estrellita

Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.

6 Jan 2012

Losartan may help prevent smoking-related COPD

Working with mice, scientists at Johns Hopkins have successfully used a commonly prescribed blood pressure medicine, losartan (Cozaar), to prevent almost all of the lung damage caused from two months of exposure to cigarette smoke. The treatment specifically targeted lung tissue breakdown, airway wall thickening, inflammation and lung over-expansion.

4 Jan 2012

Quantitative CT can offer valuable prognostic information for COPD patients

National Jewish Health researchers and their colleagues in the COPDGene research consortium report that a computerized form of radiology, known as quantitative CT, can offer valuable prognostic information for patients and doctors beyond the standard breathing tests most commonly used to evaluate chronic obstructive pulmonary disease.

4 Jan 2012

Lostartan can reduce cigarette smoke-induced lung injury

Chronic obstructive pulmonary disease (COPD) is among the most common causes of death in the US. It is a smoking-related disease for which there are currently no disease-altering therapies. However, hope that one could be developed is now provided by the work of Enid Neptune and colleagues, at Johns Hopkins University, Baltimore, in a mouse model of lung disease caused by exposure to cigarette smoke.

20 Dec 2011

The Academy of Nutrition and Dietetics to expand coverage of MNT

The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.

19 Dec 2011

Dust storms have adverse effect on hospital EDs for COPD

A new study published in the journal Respirology reveals that dust storms have an adverse effect on emergency hospital admission for chronic lung disease, often known as chronic obstructive pulmonary disease.

6 Dec 2011

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.

28 Nov 2011

World citizen number 7 billion more likely to contract diabetes or other NCDs

World citizen number 7 billion is less likely to die from infectious diseases like measles or even AIDS, and more likely to contract diabetes or other non-communicable diseases (NCDs), as they are now the leading causes of deaths globally.

15 Nov 2011

Mylan acquires rights to Pfizer's inhalation technology platform

Mylan Inc. today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform.

10 Nov 2011